表紙
市場調查報告書

全球細胞活性分析市場:成長,趨勢,預測

Cell Viability Assays Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 907042
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
全球細胞活性分析市場:成長,趨勢,預測 Cell Viability Assays Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 115 Pages
簡介

本報告提供全球細胞活性分析市場相關調查,提供市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業簡介等相關資訊。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場趨勢

  • 市場概要
  • 推動市場的要素
  • 阻礙市場的要素
  • 波特的五力分析

第5章 市場區隔

  • 各產品
    • 消耗品
      • 試劑
      • 化驗套件
      • 其他
    • 計量儀器
      • 自動細胞計數器
      • 流式細胞技術
      • 分光光度計
      • 其他
  • 各用途
    • 藥物研發·開發
    • 幹細胞研究
    • 臨床,診斷
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭環境

  • 企業簡介
    • Abcam Plc
    • Becton Dickinson & Company
    • Bio-Rad Laboratories
    • Biotek Instruments
    • Creative Bioarray
    • GE Healthcare
    • Merck KGaA
    • Perkin Elmer
    • Promega Corporation
    • Thermo Fischer Scientific Inc.

第7章 市場機會與未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 65547

The Cell Viability Assays Market is expected to register a CAGR of 7.7% during the forecast period. The major factors for the growth of the cell viability assays market include the growing burden of chronic and infectious diseases, rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics.

Furthermore, according to the World Health Organization (WHO), chronic diseases are expected to increase by 57% by 2020. Furthermore, as per the Globocan Database, the number of new cases was estimated to increase from 18.1 million to 29.4 million, between 2018 and 2040.

In the emerging markets, cancer and heart diseases are becoming the main causes of death, as a result of urbanization, sedentary lifestyles, changing diets, rising obesity levels, and widespread availability of tobacco products. Thus, the growing burden of chronic diseases is expected to boost cell-based research, resulting in the high growth of the market.

Key Market Trends

Stem Cell Research Segment is Estimated to Register the Fastest Growth Over the Forecast Period

The stem cell research segment is estimated to register the fastest growth, owing to the rising R&D activities and funding from various organizations. According to the National Institutes of Health (NIH), an estimated USD 1,748 million was granted for stem cell research in 2018.

The technological advancements play a significant role in the future with multiple experiments in pluripotent stem cells being the center for exciting growth. For instance, in September 2018, researchers from China and the United States have developed a novel bio-ink that can efficiently bioprint, culture, and expand the human induced pluripotent stem cells and this type of innovation is likely to fuel the market growth in future years.

Thus, considering all the aforementioned factors, the market is expected to witness high growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America holds a major share for the cell viability assays market, and it is expected to witness a similar trend over the forecast period, without significant fluctuations. The region is dominating the market, due to various factors, like the increasing incidences of chronic diseases, rise in investment initiatives by governments, and high-quality infrastructure for clinical and laboratory research.

According to the estimates of the American Cancer Society, in the United States, there were 1,735,350 new cancer cases diagnosed and 609,640 deaths due to cancer in 2018. In addition, it is estimated that in 2020 there will be about 1.8 million new cancer cases diagnosed and approximately 606,520 cancer deaths in the United States.​

Furthermore, in the United States, there is a rise in the funding for cell-based research, which is expected to propel the overall growth of the cell viability assay market, over the forecast period.

Competitive Landscape

The cell viability assays market is fragmented competitive owing to the presence of various small and large market players. Some of the market players are Abcam PLC, Becton Dickinson & Company, Bio-Rad Laboratories, Biotek Instruments, Creative Bioarray, GE Healthcare, Merck KGaA, Perkin Elmer, Promega Corporation, and Thermo Fischer Scientific Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Chronic and Infectious Diseases
    • 4.2.2 Rising Demand for Cell-based Assays in Research
    • 4.2.3 Increasing Focus on the Development of Cell-based Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Limitations of the Assays
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Product
    • 5.1.1 Consumables
      • 5.1.1.1 Reagents
      • 5.1.1.2 Assay Kits
      • 5.1.1.3 Other Consumables
    • 5.1.2 Instruments
      • 5.1.2.1 Automated Cell Counters
      • 5.1.2.2 Flow Cytometers
      • 5.1.2.3 Spectrophotometers
      • 5.1.2.4 Other Instruments
  • 5.2 Application
    • 5.2.1 Drug Discovery and Development
    • 5.2.2 Stem Cell Research
    • 5.2.3 Clinical and Diagnostic Applications
    • 5.2.4 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abcam PLC
    • 6.1.2 Becton Dickinson & Company
    • 6.1.3 Bio-Rad Laboratories
    • 6.1.4 Biotek Instruments
    • 6.1.5 Creative Bioarray
    • 6.1.6 GE Healthcare
    • 6.1.7 Merck KGaA
    • 6.1.8 Perkin Elmer
    • 6.1.9 Promega Corporation
    • 6.1.10 Thermo Fischer Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS